Annals of Surgical Oncology

, Volume 20, Issue 7, pp 2261–2265 | Cite as

Level VII is an Important Component of Central Neck Dissection for Papillary Thyroid Cancer

  • Laura Y. Wang
  • Mark A. Versnick
  • Anthony J. Gill
  • James C. Lee
  • Stanley B. Sidhu
  • Mark S. Sywak
  • Leigh W. Delbridge
Endocrine Tumors

Abstract

Background

Therapeutic central neck dissection (CND) is an accepted part of the management of papillary thyroid carcinoma (PTC), while prophylactic CND remains controversial. Regardless of the indication for CND, the lower anatomic border of the central compartment, specifically the inclusion or otherwise of level VII, is not always clearly defined in the literature. This study aimed to determine if the routine inclusion of level VII lymph node dissection as part of CND confers increased utility in the detection of macrometastatic lymph nodes compared with level VI dissection alone.

Method

This was a prospective cohort study of patients undergoing CND for PTC at a tertiary referral center. All patients received either a prophylactic or therapeutic CND. The CND specimens were divided by the surgeon into level VI and level VII at the level of the suprasternal notch and submitted separately for histopathology. Criteria for macroscopic lymph node disease were taken from the American Joint Committee on Cancer (AJCC) recommendations for breast cancer.

Results

A total of 45 patients with PTC underwent total thyroidectomy and routine CND, at a tertiary referral center; 77 % of the therapeutic CND group had positive level VI lymph nodes, and 38 % had positive level VII lymph nodes. Of the prophylactic CND group, 50 % of patients had positive level VI nodes and 16 % has positive level VII nodes detected. All patients with positive level VII lymph nodes in the prophylactic CND group had macrometastatic disease. Temporary hypocalcemia rate was 31 % in the therapeutic group and 6 % in the prophylactic CND group. One patient experienced permanent hypoparathyroidism. There was no vascular injury or recurrent laryngeal nerve palsy in either group.

Conclusions

CND incorporating both level VI and level VII can be undertaken safely through a cervical incision with no increased risk of permanent complications of hypoparathyroidism or recurrent laryngeal nerve injury. Failure to include level VII as part of CND will leave significant macrometastatic nodal disease behind in both therapeutic and prophylactic dissections. As level VII is in direct anatomic continuity with the pretracheal level VI nodes, it should be routinely included as part of every CND.

References

  1. 1.
    Rosenbaum MA, McHenry CR. Contemporary management of papillary carcinoma of the thyroid gland. Expert Rev Anticancer Ther. 2009;9:317–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Mazzaferri EL Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–28.PubMedCrossRefGoogle Scholar
  3. 3.
    Lundgren CI, Hall P, Ekbom A, Frisell J, Zedenius J, Dickman PW. Incidence and survival of Swedish patients with differentiated thyroid cancer. Int J Cancer. 2003;106:569–73.PubMedCrossRefGoogle Scholar
  4. 4.
    Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.PubMedCrossRefGoogle Scholar
  5. 5.
    Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg. 1994;18:559–67; discussion 567–8.Google Scholar
  6. 6.
    Hughes CJ, Shaha AR, Shah JP, Loree TR. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck. 1996;18:127–32.PubMedCrossRefGoogle Scholar
  7. 7.
    American Thyroid Association Surgery Working, Carty SE, Cooper DS, Doherty GM, Duh QY, Kloos RT, Mandel SJ, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid. 2009;19:1153–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC cancer staging manual. 7th ed., New York: Springer, 2010.Google Scholar
  9. 9.
    Crile GJ. The pattern of metastasis of carcinoma of the thyroid. Ann Surg. 1956; 143:580–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996;5:43–63.PubMedGoogle Scholar
  11. 11.
    Mulla M. Central cervical lymph node metastases in papillary thyroid cancer: a systematic review of imaging-guided and prophylactic removal of the central compartment. Clin Endocrinol (Oxf). 2012;76:131–6.CrossRefGoogle Scholar
  12. 12.
    Block MA, Miller JM, Horn RC Jr. Significance of mediastinal lymph node metastases in carcinoma of the thyroid. Am J Surg. 1972;123:702–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Cheema Y, Repplinger D, Elson D, Chen H. Is tumor size the best predictor of outcome for papillary thyroid cancer? Ann Surg Oncol. 2006;13:1524–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Hay ID, Bergstralh EJ, Grant CS, McIver B, Thompson GB, van Heerden JA, et al. Impact of primary surgery on outcome in 300 patients with pathologic tumor-node-metastasis stage III papillary thyroid carcinoma treated at one institution from 1940 through 1989. Surgery. 1999;126:1173–81; discussion 1181–2.Google Scholar
  15. 15.
    Ito Y, Miyauchi A. Lateral and mediastinal lymph node dissection in differentiated thyroid carcinoma: indications, benefits, and risks. World J Surg. 2007;31:905–15.PubMedCrossRefGoogle Scholar
  16. 16.
    Noguchi M, Kumaki T, Taniya T, Segawa M, Nakano T, Ohta N, et al. Impact of neck dissection on survival in well-differentiated thyroid cancer: a multivariate analysis of 218 cases. Int Surg. 1990;75:220–4.PubMedGoogle Scholar
  17. 17.
    Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90:5723–9.PubMedCrossRefGoogle Scholar
  18. 18.
    DeGroot LJ, Kaplan EL, McCormick M, Straus FH, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414–24.PubMedCrossRefGoogle Scholar
  19. 19.
    Shaha AR, Shah JP, Loree TR. Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol. 1996;3:534–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Steinmuller T, Klupp J, Rayes N, Ulrich F, Jonas S, Gräf KJ, et al. Prognostic factors in patients with differentiated thyroid carcinoma. Eur J Surg. 2000;166:29–33.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Laura Y. Wang
    • 1
  • Mark A. Versnick
    • 1
  • Anthony J. Gill
    • 1
    • 2
  • James C. Lee
    • 1
  • Stanley B. Sidhu
    • 1
  • Mark S. Sywak
    • 1
  • Leigh W. Delbridge
    • 1
  1. 1.University of Sydney Endocrine Surgery UnitSydneyAustralia
  2. 2.Department of Anatomical PathologyRoyal North Shore Hospital and University of SydneySydneyAustralia

Personalised recommendations